Lumryz (sodium oxybate) is a brand-name oral suspension that’s prescribed for symptoms of narcolepsy in adults. Lumryz has interactions with alcohol, some other drugs, and certain supplements.

Lumryz (sodium oxybate) is a prescription drug used to treat excessive daytime sleepiness or cataplexy from narcolepsy. Lumryz can cause side effects that range from mild to serious. Examples ...

Lumryz (sodium oxybate) is a brand-name oral liquid prescribed for narcolepsy in adults and certain children. As with other drugs, Lumryz can cause side effects, such as dizziness, nausea ...

Avadel Pharmaceuticals announced a projected fourth-quarter net revenue of approximately $50 million from sales of LUMRYZ™, reflecting a more than 150% increase from the same period last year.

Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 ...

"2024 was a pivotal year for Avadel, marked by consistent patient adoption of LUMRYZ and overwhelmingly positive feedback from both patients and providers about the transformative benefits of once ...

Sales of its narcolepsy drug, LUMRYZ rose by 150% YoY. AVDL expects net product revenue for 2025 in the range of $240 million to $260 million. Get Pro-Level Earnings Insights Before the Market ...